JPH04351964A - スクリーニング方法およびそれの適用方法 - Google Patents
スクリーニング方法およびそれの適用方法Info
- Publication number
- JPH04351964A JPH04351964A JP3307281A JP30728191A JPH04351964A JP H04351964 A JPH04351964 A JP H04351964A JP 3307281 A JP3307281 A JP 3307281A JP 30728191 A JP30728191 A JP 30728191A JP H04351964 A JPH04351964 A JP H04351964A
- Authority
- JP
- Japan
- Prior art keywords
- dehydroepiandrosterone
- measuring
- progression
- human immunodeficiency
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 31
- 238000012216 screening Methods 0.000 title 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims abstract description 25
- 230000028327 secretion Effects 0.000 claims abstract description 9
- 208000024891 symptom Diseases 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 229960002847 prasterone Drugs 0.000 claims description 28
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 22
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 22
- 238000003018 immunoassay Methods 0.000 claims description 17
- 210000001124 body fluid Anatomy 0.000 claims description 14
- 239000010839 body fluid Substances 0.000 claims description 14
- 238000005259 measurement Methods 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 238000001030 gas--liquid chromatography Methods 0.000 claims description 5
- 230000000984 immunochemical effect Effects 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 3
- 102000018358 immunoglobulin Human genes 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims 14
- QGXBDMJGAMFCBF-UHFFFAOYSA-N Etiocholanolone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC21 QGXBDMJGAMFCBF-UHFFFAOYSA-N 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- QGXBDMJGAMFCBF-LUJOEAJASA-N epiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC[C@H]21 QGXBDMJGAMFCBF-LUJOEAJASA-N 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 abstract description 9
- 208000037357 HIV infectious disease Diseases 0.000 abstract description 8
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract description 8
- 208000030507 AIDS Diseases 0.000 description 17
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 12
- 238000003556 assay Methods 0.000 description 8
- 102000003992 Peroxidases Human genes 0.000 description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 description 7
- 229960000890 hydrocortisone Drugs 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 238000005534 hematocrit Methods 0.000 description 5
- 230000000652 homosexual effect Effects 0.000 description 5
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000005497 microtitration Methods 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005184 men's health Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- -1 dipsticks Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- AIDS & HIV (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE326690A IE63418B1 (en) | 1990-09-10 | 1990-09-10 | Progression risk of HIV by assay of dehydroepiandrosterone in body fluid |
| IE3266/90 | 1990-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04351964A true JPH04351964A (ja) | 1992-12-07 |
Family
ID=11038235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3307281A Pending JPH04351964A (ja) | 1990-09-10 | 1991-09-09 | スクリーニング方法およびそれの適用方法 |
Country Status (6)
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4230684A (en) * | 1978-03-16 | 1980-10-28 | Cornell Research Foundation, Inc. | Method for determining steroids in human body liquids |
| NL194728C (nl) * | 1987-04-16 | 2003-01-07 | Hollis Eden Pharmaceuticals | Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan. |
| JPH04503110A (ja) * | 1989-02-01 | 1992-06-04 | イー・アイ・デュポン・ドゥ・ヌムール・アンド・カンパニー | ＡＩＤＳ進行監視用 ＨＩＶ ｐ１７ アッセイ |
| JPH02213766A (ja) * | 1989-02-15 | 1990-08-24 | Mochida Pharmaceut Co Ltd | 免疫測定用試薬および免疫測定器具 |
-
1990
- 1990-09-10 IE IE326690A patent/IE63418B1/en not_active IP Right Cessation
-
1991
- 1991-09-09 DE DE4129932A patent/DE4129932A1/de not_active Withdrawn
- 1991-09-09 FR FR9111118A patent/FR2666657A1/fr active Granted
- 1991-09-09 JP JP3307281A patent/JPH04351964A/ja active Pending
- 1991-09-09 IT ITMI912378A patent/IT1255009B/it active IP Right Grant
- 1991-09-09 GB GB9119256A patent/GB2249833B/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| FR2666657A1 (fr) | 1992-03-13 |
| IT1255009B (it) | 1995-10-11 |
| FR2666657B1 (US20100268047A1-20101021-C00003.png) | 1997-02-21 |
| DE4129932A1 (de) | 1992-03-12 |
| GB2249833A (en) | 1992-05-20 |
| GB2249833B (en) | 1994-09-07 |
| ITMI912378A1 (it) | 1993-03-09 |
| IE63418B1 (en) | 1995-04-19 |
| GB9119256D0 (en) | 1991-10-23 |
| ITMI912378A0 (it) | 1991-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rao et al. | An avidin-biotin microELISA for rapid measurement of total and allergen-specific human IgE | |
| JP2017151120A (ja) | 非特異的結合を減少させるためのイムノアッセイ方法及び試薬 | |
| US5480776A (en) | Method for prediction of premature labor | |
| WO1993003381A1 (en) | Assay for free secretory component and methods for monitoring organ rejection | |
| DeMars et al. | Simultaneous measurement of total and IgA-conjugated alpha 1-microglobulin by a combined immunoenzyme/immunoradiometric assay technique. | |
| Re et al. | Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy | |
| Soda et al. | C1q and C3 in bronchoalveolar lavage fluid from patients with summer-type hypersensitivity pneumonitis | |
| Usui et al. | Serum uromodulin is a novel renal function marker in the Japanese population | |
| JP4256266B2 (ja) | ヒトｈ−ｆａｂｐを検出してアントラサイクリン系抗癌性化学療法剤による心臓毒性を判定する方法、およびそのための試薬 | |
| EP0835449A1 (en) | Method for the simultaneous detection of different antibodies and/or antigens | |
| JP5952313B2 (ja) | Ｈｉｖ疾病の進行の予後診断法 | |
| WO2017179611A1 (ja) | 硫酸化多糖類を用いた免疫学的測定法 | |
| JPH04351964A (ja) | スクリーニング方法およびそれの適用方法 | |
| JPH11190734A (ja) | クローン病の検査方法および検査用キット | |
| JPH11287801A (ja) | 免疫学的測定法および免疫学的測定用キット | |
| US5108891A (en) | Aids assay | |
| Newman et al. | Murine monoclonal antibody adsorbed onto vinylidene fluoride floccules used to eliminate antibody interference in" sandwich"-type immunoassays. | |
| Contini et al. | Evidence of cerebrospinal fluid free kappa light chains in AIDS patients with Toxoplasma gondii encephalitis | |
| RU2523413C1 (ru) | СПОСОБ ДИАГНОСТИКИ РЕВМАТОИДНОГО АРТИРИТА ПО НАЛИЧИЮ АНТИТЕЛ К МОДИФИЦИРОВАННОМУ ЦИНТРУЛЛИНИРОВАННОМУ ВИМЕНТИНУ (Anti-MCV) В РОТОВОЙ ЖИДКОСТИ | |
| Singh et al. | Canadian Public Health Laboratory Network laboratory guidelines for the use of point‐of‐care tests for the diagnosis of syphilis in Canada | |
| WO2017018939A1 (en) | Methods and kit for differentiating hiv-1 and hiv-2 antibodies | |
| JP2000193662A (ja) | 尿中シスタチンｃ測定試薬及び診断方法並びにキット | |
| Tandon | Use of enzyme linked immunosorbent assay in intestinal and extra-intestinal amoebiasis (amoebic liver abscess) | |
| JPH11248703A (ja) | 遊離ハプテンの免疫学的測定法 | |
| JPH0772149A (ja) | 肝癌又は肝硬変の診断薬及び診断法 |